Currently, a phase 1 clinical trial (NCT03696030) of HER2-targeted CAR-T cells in the treatment of HER-2-positive breast cancer patients with recurrent brain or leptomeningeal metastases is in progress, and other basic frontier experiments regarding BM have also been carried out (Table 2). The gene discussed is ERBB2; the disease is breast carcinoma.